Press release
Cataract Clinical Trials Analysis 2025: Topical Small Molecules, Regenerative Therapies, and Next-Gen IOLs Aim to Delay or Replace Surgical Intervention | DelveInsight
Cataract Clinical Trials Analysis
Emerging programs explore topical lanosterol and oxysterol derivatives, antioxidants, and crystallin stabilizers designed to prevent or reverse lens opacity. Early-phase data show potential for improved lens transparency and visual acuity, though no approved pharmacologic therapy exists yet.
Parallel advances in lens regeneration and drug-eluting intraocular lenses (IOLs) target restoration of native lens clarity and prevention of postoperative complications.
Late-stage studies increasingly pair functional vision endpoints with objective lens densitometry to demonstrate both structural and clinical benefit-signaling a new phase of innovation that could redefine cataract management over the next decade.
Interested in learning more about the current treatment landscape and the key drivers shaping the cataract pipeline? Click here: https://www.delveinsight.com/report-store/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Key Takeaways from the Cataract Pipeline Report
• DelveInsight's cataract pipeline analysis depicts a strong space with 5+ active players working to develop 5+ pipeline drugs for cataract treatment.
• The leading cataract companies include Nacuity Pharmaceuticals, CGeneTech, Melt Pharmaceuticals, Plex Pharmaceuticals, and others are evaluating their lead assets to improve the cataract treatment landscape.
• Key cataract pipeline therapies in various stages of development include NPI 002, CGT 1507, Research programme: ocular therapeutics, and others.
• In May 2025, Atia Vision, a Shifamed portfolio company, received FDA IDE approval to begin a feasibility study of its OmniVuTM Lens System-an innovative intraocular lens aimed at restoring dynamic vision after cataract surgery, surpassing current presbyopia-correcting lenses.
• In March 2025, Bausch + Lomb (NYSE/TSX: BLCO) voluntarily recalled its enVista intraocular lenses following reports of unexplained complications.
• In November 2024, Melt Pharmaceuticals announced positive topline results from its Phase III trial of MELT-300, a non-IV, non-opioid sedation tablet for cataract surgery, meeting FDA-agreed criteria for regulatory submission.
• In June 2024, Alcon (SIX/NYSE: ALC) announced that its UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS) received FDA 510(k) clearance, marking the first innovations from its Unity portfolio.
Request a sample and discover the recent breakthroughs happening in the cataract pipeline landscape @ https://www.delveinsight.com/report-store/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Cataract Overview
Cataracts are a common eye condition characterized by the clouding of the eye's natural lens, leading to blurred vision and difficulty seeing clearly. They develop gradually, often due to aging, but can also result from factors like diabetes, trauma, or prolonged exposure to UV light. Symptoms include faded colors, glare, halos around lights, and difficulty with night vision. Diagnosis is made through a comprehensive eye exam. While early cataracts may be managed with stronger glasses or lighting, surgery to replace the cloudy lens with an artificial one is the most effective treatment and is commonly performed with high success rates.
Find out more about cataract medication @ https://www.delveinsight.com/report-store/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Cataract Treatment Analysis: Drug Profile
NPI 002: Nacuity Pharmaceuticals
Nacuity Pharmaceuticals has developed an intravitreal implant prototype containing NPI-002, a small antioxidant molecule designed to slow cataract progression, along with a proprietary injector. The company has completed non-clinical testing, obtained HREC approval, and plans to begin a Phase 1/2 clinical trial in Australia for NPI-002 in the fourth quarter of 2021.
CGT 1507: CGeneTech
CGT 1507 is a small molecule targeting proteolytic enzymes. Currently in the pre-clinical stage, this drug is being developed for the treatment of cataracts.
Research Programme: Ocular Therapeutics - Plex Pharmaceuticals
Plex Pharmaceuticals is developing CAP 1160, a small molecule targeting HSP27 heat-shock protein modulators, as part of its ocular therapeutics program. The molecule aims to enhance the chaperone-like activity (CLA) of alpha-crystallin (AC), a key protein in the eye lens, to reverse, slow, or prevent cataract formation. By improving AC's CLA, Plex aims to protect damaged lens proteins and prevent aggregation, which is critical for maintaining lens transparency and preventing cataract development.
Learn more about the novel and emerging cataract pipeline therapies @ https://www.delveinsight.com/report-store/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Cataract Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule
Scope of the Cataract Pipeline Report
• Coverage: Global
• Key Cataract Companies: Nacuity Pharmaceuticals, CGeneTech, Plex Pharmaceuticals, and others.
• Key Cataract Pipeline Therapies: NPI 002, CGT 1507, Research programme: ocular therapeutics, and others.
Dive deep into rich insights for drugs used for cataract treatment; visit @ https://www.delveinsight.com/report-store/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Cataract Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Cataract Pipeline Therapeutics
6. Cataract Pipeline: Late-Stage Products (Phase III)
7. Cataract Pipeline: Mid-Stage Products (Phase II)
8. Cataract Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cataract Clinical Trials Analysis 2025: Topical Small Molecules, Regenerative Therapies, and Next-Gen IOLs Aim to Delay or Replace Surgical Intervention | DelveInsight here
News-ID: 4212277 • Views: …
More Releases from DelveInsight
Spinal Implants Market Size Report 2032: Market Porter's Five Forces Analysis, M …
DelveInsight's Spinal Implants Market Insights Report 2032 provides the current and forecast market analysis, individual leading Spinal Implants Companies market shares, challenges, Spinal Implants Market Drivers, barriers, trends, and key market Spinal Implants companies in the market.
To read more about the latest highlights related to the Spinal Implants Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/spinal-implants-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Spinal…
Genome Editing Market Size Report 2032: Market Porter's Five Forces Analysis, Ma …
DelveInsight's Genome Editing Market Insights Report 2032 provides the current and forecast market analysis, individual leading Genome Editing Companies market shares, challenges, Genome Editing Market Drivers, barriers, trends, and key market Genome Editing companies in the market.
To read more about the latest highlights related to the Genome Editing Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/genome-editing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Genome Editing Market…
Retinopathy of Prematurity Therapeutics Market: Early-Stage Pipeline and FDA Des …
The Retinopathy of Prematurity treatment market is expected to witness significant growth in the coming years, primarily driven by advancements in diagnostic technologies and the development of novel therapeutics by key players such as Novartis, Regeneron, Bayer, FeliQS Corporation, and Infant Bacterial Therapeutics, among others. This growth trajectory is further supported by the rising awareness about Retinopathy of Prematurity management, improvements in neonatal care units, and increasing focus on preventive…
Chronic Kidney Disease Market Evolution: Novel Drugs, AI Integration, and Combin …
The chronic kidney disease (CKD) treatment market is witnessing robust expansion across the 7MM. This upward trajectory is primarily fueled by increasing disease prevalence, growing aging populations, rising diabetes and hypertension cases, and the emergence of innovative therapies from key chronic kidney disease players including AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Vifor Pharma, Otsuka Pharmaceutical, Reata Pharmaceuticals, Akebia Therapeutics, and Kyowa Kirin, among others, who are actively advancing the CKD…
More Releases for Cataract
Transformative Trends Impacting the Cataract Surgery Devices And Equipment Marke …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Cataract Surgery Devices And Equipment Market Size By 2025?
The market size for cataract surgery devices and equipment has shown a consistent growth trend in recent years. It is projected to increase from $13.97 billion in 2024 to $14.52 billion in 2025, exhibiting a compound…
Cataract Pipeline: Emerging Non-Surgical Solutions and Leading Companies Shaping …
The therapeutic landscape for Cataract, the leading cause of blindness globally, is undergoing a paradigm shift as researchers and biopharmaceutical companies explore non-surgical and disease-modifying alternatives to conventional cataract extraction surgery. Advances in molecular biology, oxidative stress modulation, and crystallin protein stabilization have opened new avenues for pharmacological intervention. Companies like Nacuity Pharmaceuticals, CGeneTech, and Plex Pharmaceuticals are pioneering efforts to develop novel agents aimed at delaying, halting, or reversing…
Cataract Surgery Devices Market - Innovation Meets Precision: Elevate Cataract S …
Newark, New Castle, USA: The "Cataract Surgery Devices Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Cataract Surgery Devices Market: https://www.growthplusreports.com/report/cataract-surgery-devices-market/7846
This latest report researches the industry structure,…
Intraocular Lens Implants for Cataract Market is Driven by the Increasing Incide …
The proposed Intraocular Lens Implants for Cataract Market report will encompass all the qualitative & quantitative aspects including the market size, market estimates, growth rates & forecasts & hence will give you a holistic view of the market. The study also includes detailed analysis of market drivers, restraints, technological advancements & competitive landscape along with various micro & macro factors influencing the market dynamics.
The Intraocular Lens Implants for Cataract Market…
Potential Opportunities of Cataract Surgical Devices Market
The global cataract surgical devices market size is projected to reach USD 9.98 billion by the end of 2026. The high prevalence of cataract disorders will open up a huge potential for market growth. According to a report published by Fortune Business Insights, titled "Cataract Surgical Devices Market Size, Share & Industry Analysis, By Product Type (Phacoemulsification Systems, Femtosecond Laser, Intraocular Lenses, Ophthalmic Viscoelastic Devices & Other Consumables), By End-user…
Cataract Surgery Devices Market Opportunity Analysis, 2018-2026
Cataract surgery devices are used during the surgical procedures to treat cataract, which is an eye disorder that causes clouding of the lens leading to defects in vision. Cataract is one of the most widespread disease causing blindness and it reduces vision ability. Cataract is often encountered to develop slowly and affect either one or both the eyes.
Although cataract does not interfere with the eyesight in the early stages, it…
